Seaport Therapeutics has dosed the first patient in its Phase 2b BUOY-1 study of GlyphAllo (SPT-300) for major depressive disorder ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE